Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 807

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 6
Chunk 807
---
 of the Company’s development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the “ECS”), a network of receptors and neurotransmitters that form a biochemical communication system throughout the body. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer. The accounting policies of the life science segment are as described in the summary of significant accounting policies. The CODM evaluates the performance of the life science segment based on the Company’s net loss as reported on the income statement as consolidated net loss. The Company’s segment assets are reported on the balance sheet as its total consolidated assets. The Company has not generated any revenue since its inception and expects to continue to incur losses into the foreseeable future as it continues to conduct research and development related activities through all stages of product development and clinical trials and subsequently seek approval from the respective regulatory authorities. The Company’s CODM utilizes cash forecast models to determine the Company’s investment in the life sciences segment. These models are reviewed regularly to monitor the Company’s operating results and performance and compared to the Company’s cash-based forecasts.   Year ended   December 31,   2024  2023        General and administrative      Employee and director compensation $1,173  $1,091 Stock-based compensation  501   710 Professional fees  1,133   1,101 Other general and administrative (a)  1,308   1,332       Total general and administrative $4,115  $4,234   Year ended   December 31,   2024  2023        Research and development      Employee compensation $1,166  $983 Stock-based compensation  317   310 Professional fees  5,169   4,531 Research and development tax credits (b)  (1,349)  (1,206)Other research and development (c)  690   1,078       Total research and development $5,993  $5,696   (a)Consists of sales and marketing, investor relations, travel and other office expenses.  (b)Reflects tax credits from United Kingdom government recorded directly as a reduction of research and development expense upon receipt.  (c)Consists of supplies and other items used in research and development activities.  

NOTE 4 –